Barclays Raises Privia Health (PRVA) PT to $24 on Strong Q1 Fee-for-Service Performance

On Tuesday, Barclays analyst Andrew Mok increased the price target on Privia Health Group Inc. (NASDAQ:PRVA) to $24 from $23, while maintaining an Equal Weight rating on the shares.

This revision follows Privia Health’s Q1 2025 report, which demonstrated steady progress with modest outperformance in its fee-for-service business.

A physician leveraging innovative technology to enable their patient care decisions.

In Q1, Privia Health reported a 12.8% year-over-year increase in Practice Collections and reached $798.6 million. This growth contributed to an overall 35.1% rise in Adjusted EBITDA to $26.9 million, and an expansion of the EBITDA margin by 4.6% year-over-year. The company also successfully managed its expenses and showcased a clear path to achieving 20% EBITDA growth by 2026.

Privia Health’s strategic expansion, which includes the entry into the Arizona market with a $95 million transaction for IMS, which is a large multi-specialty practice, is anticipated to be EBITDA positive by Q4 2025. This will further support the company’s fee-for-service operations. Privia Health Group Inc. (NASDAQ:PRVA) operates as a national physician-enablement company and collaborates with physician practices, health plans, and health systems. It offers technology and population health tools to enhance workflows.

While we acknowledge the potential of PRVA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PRVA and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.